Literature DB >> 10402481

Glycyrrhizin protects mice from concanavalin A-induced hepatitis without affecting cytokine expression.

T Okamoto1, T Kanda.   

Abstract

The administration of concanavalin A (Con A) to mice induces cytokine-dependent hepatitis. In the present study, the effect of glycyrrhizin on Con A-induced hepatitis was examined. Treatment of mice with Con A (0.2 mg/mouse, i.v.) induced elevation of the plasma transaminase activities at 24 h. Mice were treated with glycyrrhizin (100, 200 and 400 mg/kg, i.p.), and glycyrrhizin at the doses of 200 and 400 mg/kg inhibited the Con A-induced elevation of the plasma transaminase activities. At 1 h after Con A treatment, interferon-gamma, tumor necrosis factor-alpha, interleukin-2 and interleukin-6 proteins were released into the plasma. Although treatment with glycyrrhizin at 200 mg/kg inhibited Con A-induced hepatitis, it did not affect the release of any of these Con A-induced cytokines into the plasma. The present results clearly show that glycyrrhizin inhibited Con A-induced hepatitis without affecting cytokine expression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10402481     DOI: 10.3892/ijmm.4.2.149

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  8 in total

1.  Carbenoxolone blocks endotoxin-induced protein kinase R (PKR) activation and high mobility group box 1 (HMGB1) release.

Authors:  Wei Li; Jianhua Li; Andrew E Sama; Haichao Wang
Journal:  Mol Med       Date:  2013-07-24       Impact factor: 6.354

Review 2.  Nitric oxide as a target of complementary and alternative medicines to prevent and treat inflammation and cancer.

Authors:  Lorne J Hofseth
Journal:  Cancer Lett       Date:  2008-04-25       Impact factor: 8.679

3.  Hepatic protection by glycyrrhizin and inhibition of iNOS expression in concanavalin A-induced liver injury in mice.

Authors:  Noriko Tsuruoka; Kazuki Abe; Kenjirou Wake; Masaru Takata; Akira Hatta; Tositugu Sato; Hideo Inoue
Journal:  Inflamm Res       Date:  2009-03-31       Impact factor: 4.575

Review 4.  Novel Mechanisms of Herbal Therapies for Inhibiting HMGB1 Secretion or Action.

Authors:  Andrew H Wu; Li He; Wei Long; Qiuping Zhou; Shu Zhu; Ping Wang; Saijun Fan; Haichao Wang
Journal:  Evid Based Complement Alternat Med       Date:  2015-03-02       Impact factor: 2.629

5.  An ongoing search for potential targets and therapies for lethal sepsis.

Authors:  Guo-Qiang Bao; Li He; David Lee; John D'Angelo; Hai-Chao Wang
Journal:  Mil Med Res       Date:  2015-08-08

Review 6.  Exploring the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Glycyrrhizic and Glycyrrhetinic Acids.

Authors:  Seidu A Richard
Journal:  Mediators Inflamm       Date:  2021-01-07       Impact factor: 4.711

7.  Apoptotic response through a high mobility box 1 protein-dependent mechanism in LPS/GalN-induced mouse liver failure and glycyrrhizin-mediated inhibition.

Authors:  Noriyuki Kuroda; Kouji Inoue; Tadayuki Ikeda; Yaiko Hara; Kenjiro Wake; Tetsuji Sato
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

8.  Glycyrrhizin prevents of lipopolysaccharide/D-galactosamine-induced liver injury through down-regulation of matrix metalloproteinase-9 in mice.

Authors:  Kazuki Abe; Tadayuki Ikeda; Kenjiro Wake; Tetsuji Sato; Toshitsugu Sato; Hideo Inoue
Journal:  J Pharm Pharmacol       Date:  2008-01       Impact factor: 3.765

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.